Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
h-ATG/CsA in Refractory Aplastic Anemia
NCT00944749Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Aug 2009
- Primary completion
- Dec 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antithymocyte globulin in aplastic anemia, sponsored by National Heart, Lung, and Blood Institute. Primary endpoints: Complete Response Rate at 3 Months, Absolute Neutrophil Count at 3 months and 2 more. Started Aug 2009; status: completed.
02
Drugs
antithymocyte globulin
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT00944749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00944749.